2024
MIF and CD74 as Emerging Biomarkers for Immune Checkpoint Blockade Therapy
Fey R, Nichols R, Tran T, Vandenbark A, Kulkarni R. MIF and CD74 as Emerging Biomarkers for Immune Checkpoint Blockade Therapy. Cancers 2024, 16: 1773. PMID: 38730725, PMCID: PMC11082995, DOI: 10.3390/cancers16091773.Peer-Reviewed Original ResearchImmune-related adverse eventsImmune-related adverse events developmentResponse to ICB therapyImmune checkpoint blockade therapyImmune checkpoint blockadePredictive biomarkersICB therapyCheckpoint blockade therapySerum MIF levelsBlockade therapyCheckpoint blockadeMIF levelsMalignant melanomaTreatment resistanceSolid tumorsAdverse eventsAutoimmune diseasesContext of cancerPrognostic biomarkerCancer progressionCognate receptor CD74Receptor CD74TherapyCD74Cancer
2023
Current diagnosis and management of cardiac melanoma: a case series and review
Long A, Chang J, Glahn J, Olino K, Tran T, Clune J. Current diagnosis and management of cardiac melanoma: a case series and review. Journal Of Cancer Metastasis And Treatment 2023, 9: null-null. DOI: 10.20517/2394-4722.2022.113.Peer-Reviewed Original ResearchUse of immunotherapyCardiac melanomaCardiac tumorsSurveillance imagingMalignant melanomaRoutine surveillance imagingCardiac metastasisCase seriesCDKN2A variantsClinical findingsAutopsy studyBRAF mutationsNRAS mutationsPatientsCurrent diagnosisImmunotherapyMelanomaGenetic profilingHigh rateTumorsDiagnosisImagingMetastasisTherapySymptoms
2018
Perilesional edema and blood vessel characteristics in brain metastases and implications for treatment with immune therapy.
Tran T, Jilaveanu L, Mahajan A, Goldberg S, Nguyen D, Chiang V, Kluger H. Perilesional edema and blood vessel characteristics in brain metastases and implications for treatment with immune therapy. Journal Of Clinical Oncology 2018, 36: 9572-9572. DOI: 10.1200/jco.2018.36.15_suppl.9572.Peer-Reviewed Original Research